Long Shortz with Race Oncology: First patient dosing for RC220

Tylah Tully speaks with Race Oncology (ASX:RAC) CEO Daniel Tillett after the company dosed the first patient in its RC220 Phase 1 solid tumour trial.

Race has reformulated RC220, after the initial formulation caused crystallisation in the blood.

Tillet confirmed this patient was dosed safely, with no crystallisation, paving the way for the dose escalation stage of the trial.

This video was developed in collaboration with Race Oncology, a Stockhead client at the time of publishing.

The interviews and discussions in this video are opinions only and not financial or investment advice. Viewers should obtain independent advice based on their own circumstances before making any financial decisions.